BOSTON and PHILADELPHIA, May 14, 2026 — Ontada®, a McKesson business dedicated to real-world oncology data and insights, will present new real‑world research and introduce ON.Journey, a new oncology data solution, at ISPOR 2026.

To continue advancing impactful real-world oncology research, Ontada is launching ON.Journey, a new portfolio of off-the-shelf, longitudinal oncology datasets. Built using oncology-specific artificial intelligence and natural language processing applied to structured and unstructured clinical data  from Ontada’s proprietary dataset of electronic medical records from community oncology practices, ON.Journey enables medical affairs, health economics and outcomes research (HEOR), epidemiology, and real-world evidence teams to generate rich clinical insights with speed. With claims data natively integrated, ON.Journey allows teams to analyze treatment utilization alongside clinical outcomes—without the need for custom integration or third-party linkage.

“ON.Journey reflects our focus on delivering data solutions that help life sciences teams generate evidence with greater speed and consistency,” said Christine Davis, president of Ontada. “It enables access to research-grade oncology data, supporting evolving needs across the lifecycle.”

Ontada will present 12 posters at ISPOR 2026, including four that examine real-world treatment adoption, outcomes and patterns of care across community oncology populations.

“Real‑world evidence provides important insight into how cancer care is delivered,” said Jessica K. Paulus, ScD, vice president, Real-World Research for Ontada. “The studies presented at ISPOR reflect our commitment to using high‑quality community oncology data to inform evidence generation and deepen understanding of care delivered in real world clinical practice settings.”

Highlights of Ontada’s presence at ISPOR include:

  1. Poster #HSD11: Improving Real-World Adoption of HER2-Low Therapies Through Targeted Educational Initiatives
    • Monday, May 18, 10:30 a.m. – 1:30 p.m. EDT
    • This observational study and educational initiative evaluates the use of evidence‑based educational outreach in supporting adoption of updated treatment guidelines for HER2‑low therapies.

  2. Poster #MSR66: Integrating Generative Artificial Intelligence (AI) into Biostatistical Workflows for Trial Emulation: A Framework to Accelerate Real-World Evidence Generation
    • Monday, May 18, 4:00 p.m. – 7:00 p.m. EDT
    • This research outlines a framework for applying generative AI to trial‑emulation workflows to support more scalable and reproducible real‑world evidence generation.

  3. Poster # RWD54: Evolution of Homologous Recombination Repair (HRR) Genetic Testing by Race Among Patients with Metastatic Prostate Cancer (mPC) in a Large Community Oncology Setting in the US, 2015 – 2024
    • Monday, May 18, 4:00 p.m. – 7:00 p.m. EDT
    • This retrospective, observational analysis uses structured electronic health record data to describe HRR genetic testing patterns by race among patients with metastatic prostate cancer.

  4. Poster # HSD112: Real-World Patterns of Homologous Recombination Repair Testing of Patients with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) in the US Community Oncology Setting
    • Wednesday, May 20, 9:00 a.m. – 11:30 a.m. EDT
    • This retrospective, observational cohort study examines real-world patterns of HRR genetic testing among patients, highlighting gaps in testing during earlier stages of advanced disease.

 Visit the Ontada Booth (#410) at the Pennsylvania Convention Center from May 18-20 to learn more about ON.Journey and Ontada research and data capabilities.

About Ontada®

Ontada is an oncology technology and insights business dedicated to transforming the fight against cancer. Part of McKesson Corporation, Ontada was founded on the belief that precise insights—delivered exactly at the point of need—can save more patients’ lives. Ontada connects the full patient journey by combining technologies used by The US Oncology Network and other community oncology providers with real-world data and research relied on by leading life sciences companies. For more information, visit ontada.com.

About McKesson Oncology & Multispecialty

Our Oncology & Multispecialty segment delivers a portfolio of integrated solutions that support patient care by accelerating drug development, expanding access to high-quality care close to home and ensuring life-saving therapies reach the patients who need them most. We provide practice management, technology solutions, specialty drug distribution, clinical trial and group purchasing services, along with pharmacy solutions for community-based oncology practices and multispecialty providers in retina and ophthalmology. We partner behind the scenes with healthcare providers in local communities, supporting their operations so that they can stay focused on who matters most – patients.

Media Contact

Ontada
Claire Crye
281-825-9927
Claire.Crye@McKesson.com